	C 2012 Dec 31	2013 Dec 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	15M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	2,650	2,555	3,304	2,746	2,908	2,871	3,128	3,224	2,926	3,278	3,252	3,454	3,749	3,822
Cost of Operating Revenue	1,201	1,277	1,574	1,385	1,541	1,398	1,529	1,517	1,446	1,550	1,460	1,527	1,579	1,525
Gross Profit	1,450	1,278	1,730	1,362	1,367	1,473	1,599	1,707	1,479	1,728	1,792	1,927	2,170	2,297
Gross Margin	54.7	50.0	52.4	49.6	47.0	51.3	51.1	52.9	50.6	52.7	55.1	55.8	57.9	60.1
Total Operating Expenses	1,841	2,046	2,694	2,293	2,516	2,395	2,572	2,637	2,406	2,579	2,503	2,615	2,635	2,574
Operating Profit	809	508	609	453	393	476	557	587	520	699	748	839	1,114	1,248
Operating Margin	30.5	19.9	18.4	16.5	13.5	16.6	17.8	18.2	17.8	21.3	23.0	24.3	29.7	32.6
Financing Income/(Expense) - Net	170	174	196	121	72	46	62	47	107	65	89	115	137	129
Profit before Taxes	834	711	756	578	511	540	683	306	454	779	836	816	1,260	1,406
Income Taxes	272	230	279	202	174	189	237	196	167	398	229	226	332	370
Profit after Tax	562	482	476	376	337	351	445	93	358	1,695	611	590	928	1,036
PAT Margin	21.2	18.9	14.4	13.7	11.6	12.2	14.2	2.9	12.2	51.7	18.8	17.1	24.7	27.1
EPS - Basic - ex Extraordinary Items	33.17	28.43	28.12	22.20	19.88	20.70	26.29	6.50	16.96	22.48	35.87	34.83	54.76	61.15
EPS - Diluted - ex Extraordinary Items	33.17	28.43	28.12	22.20	19.88	20.70	26.29	6.50	16.96	22.48	35.87	34.83	54.76	61.15
EBIT	809	508	609	453	393	476	557	587	520	699	748	839	1,114	1,248
EBITDA	827	528	635	478	418	514	605	669	598	767	814	909	1,181	1,314
EBITDA Margin	31.2	20.7	19.2	17.4	14.4	17.9	19.3	20.8	20.4	23.4	25.0	26.3	31.5	34.4

Balance Sheet

Abridged

Understanding Balance Sheet

Glaxosmithkline Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Dec 31	2013 Dec 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	2,647	2,624	2,589	2,174	1,674	2,186	2,009	1,775	2,203	3,708	2,494	2,798	3,410	3,606
Long-Term Investments	10	0	6	6	5	2	2	1	1	1	1	1	1	2
Property Plant & Equipment - Net	133	162	238	472	826	1,173	1,367	827	355	325	315	311	284	306
Total Non-Current Assets	442	506	640	885	1,333	1,765	1,905	1,361	915	928	835	761	701	721
Total Assets	3,088	3,130	3,224	3,055	3,004	3,947	3,911	3,133	3,115	4,633	3,327	3,557	4,108	4,324
Total Current Liabilities	836	889	500	579	720	1,600	1,454	1,022	1,355	1,698	1,326	1,525	1,905	1,779
Long Term Debt	4	4	3	2	1	1	0	27	20	8	3	6	2	17
Total Non-Current Liabilities	245	251	280	292	277	290	317	291	282	272	259	254	252	277
Total Liabilities	1,082	1,140	780	872	997	1,890	1,771	1,313	1,636	1,970	1,585	1,779	2,157	2,056
Total Shareholders' Equity	2,007	1,990	2,444	2,183	2,007	2,057	2,140	1,821	1,478	2,663	1,741	1,778	1,951	2,267
Total Equity	2,007	1,990	2,444	2,183	2,007	2,057	2,140	1,821	1,478	2,663	1,741	1,778	1,951	2,267
Total Liabilities & Equity	3,088	3,130	3,224	3,055	3,004	3,947	3,911	3,133	3,115	4,633	3,327	3,557	4,108	4,324

Cash Flow

Abridged

Understanding Cash Flow Statement

Glaxosmithkline Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Dec 31	2013 Dec 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	15M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	423	443	553	405	347	371	490	508	584	733	592	613	1,222	1,118
Working Capital - Increase/(Decrease)	52	11	-37	-124	-26	165	-4	44	46	120	-46	61	185	-98
Net CF from Operating Activities	474	454	517	281	321	536	486	552	629	853	546	674	1,407	1,020
Capital Expenditures - Net	39	30	162	208	258	385	243	155	-138	1	33	9	19	33
Net CF from Investing Activities	-271	16	1	357	215	-167	-230	-122	364	-2,011	1,041	-85	-164	278
Dividends Paid - Cash - Total	378	421	424	529	424	254	296	339	678	507	1,525	542	749	714
Debt - LT & ST - Issuance/(Retirement) - Total	0	0	-1	-1	-1	-1	0	-15	-15	-16	-17	-18	-19	-20
Net Cash Flow from Financing Activities	-440	-494	-497	-638	-511	-306	-358	-424	-693	-522	-1,542	-560	-768	-734
Free Cash Flow to Equity	435	423	353	72	62	150	242	382	753	836	497	647	1,369	966
Free Operating CF net dividend	57	-25	-70	-481	-407	-122	-102	54	-92	311	-1,023	101	633	250
Free Operating CF	435	396	353	49	17	132	194	393	585	818	502	642	1,382	964

Business Segment Analysis

FY End:

Mar 26

Glaxosmithkline Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 55.28 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 3,821.67 Cr

Assets

Pharmaceuticals (100.0%)₹ 4,323.87 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 1,247.57 Cr

Regional Segment Analysis

FY End:

Mar 26

Glaxosmithkline Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (98.6%)₹ 3,769.58 CrForeign countries (1.4%)₹ 52.09 Cr

Historical Segment Analysis

Track how Glaxosmithkline Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceuticals	35	44	31	25	55

Frequently Asked Questions

What is the revenue of Glaxosmithkline Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Glaxosmithkline Pharmaceuticals Ltd. is ₹ 3,821.67 Cr, reflecting a 1-year growth of 1.93% and a 3-year CAGR of 5.53%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Glaxosmithkline Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Glaxosmithkline Pharmaceuticals Ltd. is ₹ 1,035.98 Cr, with a 3-year earnings CAGR of 18.78%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Glaxosmithkline Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Glaxosmithkline Pharmaceuticals Ltd. is approximately ₹ 1,242.76 Cr (based on an operating margin of 32.52%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Glaxosmithkline Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Glaxosmithkline Pharmaceuticals Ltd. is 60.11. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Glaxosmithkline Pharmaceuticals Ltd.?

The debt-to-equity ratio of Glaxosmithkline Pharmaceuticals Ltd. stands at 0.01. The interest coverage ratio is 455.22x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Glaxosmithkline Pharmaceuticals Ltd.?

The estimated book value per share of Glaxosmithkline Pharmaceuticals Ltd. is 133.85 (derived from a P/B ratio of 18.20 and market price of ₹ 2,435.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Glaxosmithkline Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Glaxosmithkline Pharmaceuticals Ltd. is ₹ 1,019.70 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Glaxosmithkline Pharmaceuticals Ltd. report consolidated or standalone financials?

Glaxosmithkline Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.